 Its clinical trial was terminated prematurely.MMI-166 has an N-arylsulfonyl-α-aminocarboxylate zinc-binding group, different from the hydroxamate-zinc binding group seen in MMI-270 and Cipemastat.It also has a triaryl substitution that the other structures didn‘t have.